SCHEMBL5689288

SCHEMBL5689288

CN1CCN(CCCOc2ccc(Nc3ncc(C(=O)Nc4c(Cl)cc(F)cc4Cl)cn3)cc2F)CC1

nearest known ligand 0.48

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 2/20 0.48
EGFR P00533 6/20 0.45
ERBB2 P04626 1/20 0.45
JAK3 P52333 1/20 0.44
BTK Q06187 1/20 0.44
KDR P35968 7/20 0.44
MET P08581 8/20 0.43
LCK P06239 1/20 0.43
SRC P12931 1/20 0.43
MAPK14 Q16539 1/20 0.43
PDGFRB P09619 1/20 0.43
KIT P10721 1/20 0.43
FLT3 P36888 1/20 0.43
AURKA O14965 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5686279 0.93 CSF1R (0.50) CSF1REGFRERBB2JAK3BTK
SCHEMBL4503003 0.93 MET (0.45) CSF1REGFRJAK3BTKKDR
SCHEMBL5689079 0.91 KDR (0.47) CSF1REGFRKDRMETLCK
SCHEMBL4496504 0.88 KDR (0.52) CSF1REGFRJAK3BTKKDR
SCHEMBL4497531 0.88 KDR (0.47) CSF1REGFRKDRMETLCK
SCHEMBL5686060 0.86 KDR (0.54) CSF1REGFRJAK3BTKKDR
SCHEMBL4481044 0.85 EGFR (0.47) EGFRJAK3BTKKDRMET
SCHEMBL4488804 0.85 KDR (0.52) JAK3BTKKDRMETLCK
SCHEMBL5686300 0.84 KDR (0.50) BTKKDRMETLCKSRC
SCHEMBL5686178 0.83 CSF1R (0.52) CSF1REGFRERBB2JAK3BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1648464-A1 2-AMINO-4-HYDROXY-5-PYRIMIDINCARBOXAMID DERIVATIVES AND RELATED COMPOUNDS AS T-CELL ACTIVATION INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS AMGEN INC. (US) 2006-04-26 EP disclosed
WO-2005009443-A1 2-AMINO-4-HYDROXY-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF T CELL ACTIVATION FOR THE TREATMENT OF INFLAMMATORY DISEASES AMGEN INC. (US) 2005-02-03 WO disclosed